Work

Cytotoxic efficacy of filanesib and melphalan combination is governed by sequence of treatment in human myeloma cells

Year: 2016

Type: article

Abstract: The integration of novel agents (for example, proteasome inhibitors, IMiDS) into frontline therapy for multiple myeloma (MM) has significantly improved response rates and increased progression-free survival. Nevertheless, most patients with MM relapse often with resistant disease. 1 Several clinical trials assessing the current role of high-dose chemotherapy (HDT) with autologous stem cell transplant (ASCT) have reaffirmed the utility of HDT-ASCT for treating transplant-eligible MM patients. 2 Efforts to improve the standard conditioning regimen (single agent melphalan 200 mg/m 2 ) for ASCT have generally failed due to increased toxicity without the demonstration of superiority. 3 However, recent evidence suggests that conditioning regimens combining HDT-melphalan with novel agents (bortezomib, lenalidomide) are safer and improve patient response and outcome. 4 , 5

Source: Blood Cancer Journal

DOI: 10.1038/bcj.2016.92

Authors: E J Norris, D DeStephanis, B Tunquist, S Usmani, R Ganapathi, M Ganapathi

Institutions: Carolinas Healthcare System, Levine Cancer Institute, Array BioPharma (United States)

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $5,290